A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (MYGN), (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan’s Ministry ...

An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U ...